Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 15.26%27.43B | 11.84%8.49B | 16.98%6.93B | 19.90%6.48B | 13.38%5.52B | 8.60%23.79B | 4.76%7.6B | 19.77%5.93B | 1.01%5.41B | 11.66%4.87B |
Cost of revenue | 19.53%19.03B | 18.81%5.95B | 23.00%4.9B | 24.64%4.43B | 11.14%3.76B | 7.36%15.92B | 2.52%5.01B | 20.88%3.98B | -2.93%3.55B | 12.95%3.38B |
Gross profit | 6.62%8.39B | -1.66%2.55B | 4.58%2.03B | 10.83%2.06B | 18.49%1.76B | 11.21%7.87B | 9.38%2.59B | 17.54%1.94B | 9.56%1.86B | 8.73%1.48B |
Operating expense | 6.26%6.21B | 4.27%1.73B | 14.19%1.59B | 4.18%1.52B | 2.77%1.38B | 4.92%5.85B | 2.85%1.66B | 7.43%1.39B | 6.34%1.46B | 3.48%1.34B |
Staff costs | -1.61%2.75B | -1.92%768M | -0.30%661M | -3.54%682M | -0.47%641M | 4.76%2.8B | 9.82%783M | 6.59%663M | 2.46%707M | -0.16%644M |
Research and development costs | 29.01%1.14B | 30.92%343M | 47.49%323M | 16.51%254M | 19.25%223M | 11.03%886M | 11.49%262M | 15.87%219M | 14.14%218M | 2.19%187M |
Depreciation and amortization | 12.29%201M | ---- | ---- | ---- | ---- | 20.13%179M | ---- | ---- | ---- | ---- |
-Depreciation | 12.29%201M | ---- | ---- | ---- | ---- | 20.13%179M | ---- | ---- | ---- | ---- |
Other operating expenses | 6.65%2.12B | -3.89%420M | 18.77%601M | 9.35%585M | 0.79%511M | 1.48%1.99B | -15.64%437M | 5.20%506M | 8.74%535M | 9.03%507M |
Operating profit | 7.67%2.18B | -12.30%813M | -19.46%447M | 35.35%536M | 164.58%381M | 34.53%2.02B | 23.44%927M | 53.74%555M | 23.36%396M | 105.71%144M |
Net non-operating interest income (expenses) | 450.00%11M | 0.00%3M | 300.00%2M | 2M | 4M | 140.00%2M | 3M | 50.00%-1M | 0 | 0 |
Non-operating interest income | 100.00%26M | 16.67%7M | 200.00%6M | 133.33%7M | 200.00%6M | 85.71%13M | 100.00%6M | 100.00%2M | 50.00%3M | 100.00%2M |
Non-operating interest expense | 28.57%9M | 0.00%2M | 0.00%2M | 50.00%3M | 100.00%2M | -12.50%7M | 0.00%2M | 0.00%2M | 0.00%2M | -50.00%1M |
Total other finance cost | 50.00%6M | 100.00%2M | 100.00%2M | ---- | ---- | 0.00%4M | 0.00%1M | 0.00%1M | 0.00%1M | 0.00%1M |
Net investment income | 27.34%177M | 307.14%57M | 127.78%10M | -34.00%33M | -30.63%77M | -3.47%139M | -76.27%14M | -205.88%-36M | 233.33%50M | 208.33%111M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 2,384.62%323M | 0 | 30,700.00%308M | 1,400.00%15M | 0 | 159.09%13M | 0 | 0.00%1M | 0.00%1M | 145.83%11M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | -97.75%2M | 33.33%-2M | -102.17%-1M | 0.00%-1M | -87.23%6M | 41.27%89M | -137.50%-3M | 2,400.00%46M | -1M | -17.54%47M |
Less:Other special charges | 97.75%-2M | -33.33%2M | 102.17%1M | 0.00%1M | 87.23%-6M | -41.27%-89M | 137.50%3M | -2,400.00%-46M | --1M | 17.54%-47M |
Other non-operating income (expenses) | 2.33%44M | 25.00%15M | 0.00%5M | -26.32%14M | 42.86%10M | 10.26%43M | 300.00%12M | -16.67%5M | 18.75%19M | -50.00%7M |
Income before tax | 18.57%2.73B | -6.63%887M | 35.26%771M | 29.31%600M | 47.98%475M | 34.09%2.31B | 15.71%950M | 42.86%570M | 31.82%464M | 118.37%321M |
Income tax | 40.51%777M | 31.16%181M | 46.88%235M | 31.13%198M | 56.73%163M | 14.26%553M | -28.50%138M | 25.98%160M | 62.37%151M | 46.48%104M |
Net income | 11.64%1.96B | -13.05%706M | 30.41%536M | 28.75%403M | 43.98%311M | 41.98%1.75B | 29.30%812M | 51.66%411M | 20.85%313M | 184.21%216M |
Net income continuous operations | 11.64%1.96B | -13.05%706M | 30.73%536M | 28.43%402M | 43.78%312M | 41.86%1.75B | 29.30%812M | 50.74%410M | 20.85%313M | 185.53%217M |
Noncontrolling interests | -7.44%199M | -48.89%46M | 32.56%57M | -18.97%47M | 104.17%49M | 17.49%215M | 69.81%90M | -2.27%43M | 5.45%58M | -22.58%24M |
Net income attributable to the company | 14.32%1.76B | -8.59%660M | 29.89%478M | 39.61%356M | 37.17%262M | 46.29%1.54B | 25.78%722M | 62.11%368M | 25.00%255M | 324.44%191M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 14.32%1.76B | -8.59%660M | 29.89%478M | 39.61%356M | 37.17%262M | 46.29%1.54B | 25.78%722M | 62.11%368M | 25.00%255M | 324.44%191M |
Gross dividend payment | ||||||||||
Basic earnings per share | 14.15%206.87 | -8.85%77.64 | 30.15%56.38 | 39.42%41.91 | 36.54%30.94 | 46.06%181.22 | 25.60%85.18 | 61.82%43.32 | 24.52%30.06 | 324.34%22.66 |
Diluted earnings per share | 14.15%206.87 | -8.77%77.64 | 29.92%56.2807 | 39.42%41.91 | 36.54%30.94 | 46.06%181.22 | 25.57%85.1056 | 61.82%43.32 | 24.81%30.06 | 324.34%22.66 |
Dividend per share | 15.38%60 | -23.08%40 | 0 | 20 | 0 | 13.04%52 | 13.04%52 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |